The DOI matches its Crossref record, with a small difference in title or year.
Graftskin, a Human Skin Equivalent, Is Effective in the Management of Noninfected Neuropathic Diabetic Foot Ulcers
Abstract
OBJECTIVE— We assessed in a randomized prospective trial the effectiveness of Graftskin, a living skin equivalent, in treating noninfected nonischemic chronic plantar diabetic foot ulcers. RESEARCH DESIGN AND METHODS— In 24 centers in the U.S., 208 patients were randomly assigned to ulcer treatment either with Graftskin (112 patients) or saline-moistened gauze (96 patients, control group). Standard state-of-the-art adjunctive therapy, which included extensive surgical debridement and adequate foot off-loading, was provided in both groups. Graftskin was applied at the beginning of the study and weekly thereafter for a maximum of 4 weeks (maximum of five applications) or earlier if complete healing occurred. The major outcome of complete wound healing was assessed by intention to treat at the 12-week follow-up visit. RESULTS— At the 12-week follow-up visit, 63 (56%)Graftskin-treated patients achieved complete wound healing compared with 36(38%) in the control group (P = 0.0042). The Kaplan-Meier median time to complete closure was 65 days for Graftskin, significantly lower than the 90 days observed in the control group (P = 0.0026). The odds ratio for complete healing for a Graftskin-treated ulcer compared with a control-treated ulcer was 2.14 (95% CI 1.23-3.74). The rate of adverse reactions was similar between the two groups with the exception of osteomyelitis and lower-limb amputations, both of which were less frequent in the Graftskin group. CONCLUSIONS— Application of Graftskin for a maximum of 4 weeks results in a higher healing rate when compared with state-of-the-art currently available treatment and is not associated with any significant side effects. Graftskin may be a very useful adjunct for the management of diabetic foot ulcers that are resistant to the currently available standard of care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cellular dermal matrix is usually made up of extracellular matrix, viable cells, growth factors, etc [10,37,38].”
From Efficacy and safety of acellular dermal matrix in diabetic foot ulcer treatment: A systematic review and meta-analysis (2017) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 17
- Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE,Wagner EH: Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 22:382-387, 1999 · DOI
- Pecoraro RE, Reiber GE, Burgess EM: Pathways to diabetic limb amputation: basis for prevention. Diabetes Care 13: 513-521,1990 · DOI
- Nolan CM, Beaty HN, Bagdade JD: Further characterization of the impaired bactericidal function of granulocytes in patients with poorly controlled diabetes. Diabetes 27: 889-894,1978 · DOI
- Veves A, Akbari CM, Primavera J, Donaghue VM, Zacharoulis D, Chrzan JS, DeGirolami U, LoGerfo FW, Freeman R: Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy,vascular disease, and foot ulceration. Diabetes 47: 457-463,1998 · DOI · Paper page
- Jude EB, Boulton AJ, Ferguson MW, Appleton I: The role of nitric oxide synthase isoforms and arginase in the pathogenesis of diabetic foot ulcers: possible modulatory effects by transforming growth factor β 1. Diabetologia 42:748-757, 1999 · DOI
- American Diabetes Association: Consensus Development Conference on Diabetic Foot Wound Care (Consensus Development Conference Report). Diabetes Care 22:1354-1360, 1999 · DOI
- Falanga V, Margolis D, Alvarez O, Auletta M, Maggiacomo F, Altman M, Jensen J, Sabolinski M, Hardin-Young J, the Human Skin Equivalent Investigators Group: Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Arch Dermatol 134:293-300, 1998 · DOI
- Bell E, Ehrlich HP, Buttle DJ, Nakatsuji T: Living tissue formed in vitro and accepted as skin-equivalent tissue of full thickness. Science 211:1052-1054, 1981 · DOI
- Eaglstein WH, Iriondo M, Laszio K: A composite skin substitute(Graftskin) for surgical wounds: a clinical experience. Dermatol Surg 21: 839-843,1995 · DOI
- American Diabetes Association: Foot care in patients with diabetes mellitus (Position Statement). Diabetes Care 19 (Suppl. 1): S23-S24,1996 · DOI
- Giurini JM, Rosenblum BI, Lyons TE: Management of the diabetic foot. In The Clinical Management of the Diabetic Foot. Veves A, Ed. Totowa, NJ, Humana Press, 1998, p.303-318 · DOI
- Steed DL, the Diabetic Ulcer Study: Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 21: 71-81,1995 · DOI
- Richard JL, Parer-Richard C, Daures JP, Clouet S, Vannereau D,Bringer J, Rodier M, Jacob C, Comte-Bardonnet M: Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot: a pilot, randomized, double-blind, placebo-controlled study. Diabetes Care 18:64-69, 1995 · DOI
- Gough A, Clapperton M, Rolando N, Foster AVM, Philpott-Howard J,Edmonds ME: Randomized placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 350: 855-859,1997 · DOI
- Margolis DJ, Kantor J, Berlin JA: Healing of diabetic neuropathic foot ulcers receiving standard treatment: a meta-analysis. Diabetes Care 22: 692-695,1999 · DOI · Paper page
- Lavery LA, Armstrong DG, Vela SA, Quebedeaux TL, Fleischli JG:Practical criteria for screening patients at high risk for diabetic foot. Arch Intern Med 158:157-162, 1998 · DOI · Paper page
- Theobald VA, Lauer JD, Kaplan FA, Baker KB, Rosenberg M: `Neutral allografts': lack of allogeneic stimulation by cultured human cells expressing MHC class I and class II antigens. Transplantation 55: 128-133,1993 · DOI
Cited by
Armstrong, D. G., & Lavery, L. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67695-7 · Cited by 963
Self-citationDynamic reciprocity in the wound microenvironment
Schultz, G. S., Davidson, J. M., Kirsner, R. S., Bornstein, P., & Herman, I. M. (2011) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2011.00673.x · Cited by 490
Wound healing and treating wounds
Morton, L. M., & Phillips, T. J. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.08.068 · Cited by 475
Causes, investigation and treatment of leg ulceration
Mekkes, J. R., Loots, M. A. M., Van Der Wal, A. C., & Bos, J. D. (2003) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2003.05222.x · Cited by 381
Activity Patterns of Patients With Diabetic Foot Ulceration
Armstrong, D. G., Lavery, L. A., Kimbriel, H. R., Nixon, B. P., & Boulton, A. J. M. (2003) · Diabetes Care · doi:10.2337/diacare.26.9.2595 · Cited by 306
Self-citation
Metadata
- Authors
- Veves, A., Falanga, V., Armstrong, D. G., Sabolinski, M. L., & Study, T. A. D. F. U.
- Affiliations
- From the Joslin-Beth Israel Deaconess Foot Center and Harvard Medical School (A.V.), Boston, Massachusetts; the Department of Dermatology and Skin Surgery (V.F.), Roger Williams Medical Center, Providence, Rhode Island; the Boston University School of Medicine (V.F.), Boston, Massachusetts; the Department of Surgery (D.G.A.), Southern Arizona Veterans Affairs Medical Center, Tucson, Arizona; and Organgenesis (M.L.S.), Canton,Massachusetts.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2001-02-01
- Volume
- 24
- Issue
- 2
- Pages
- 290-295
- ISSN
- 0149-5992
- 1935-5548
- Cited by
- 643
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Graftskin, a Human Skin Equivalent, Is Effective in the Management of Noninfected Neuropathic Diabetic Foot Ulcers. https://app.cochat.ai/papers/10.2337/diacare.24.2.290
- The paper
- Veves, A., Falanga, V., Armstrong, D. G., Sabolinski, M. L., & Study, T. A. D. F. U. (2001). Graftskin, a Human Skin Equivalent, Is Effective in the Management of Noninfected Neuropathic Diabetic Foot Ulcers. Diabetes Care. https://doi.org/10.2337/diacare.24.2.290
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
